Last reviewed · How we verify

NCT03308331

HIV-1 and Brain Interaction on Smoking Comorbidity

Withdrawn NA Last updated 10 March 2020
What this trial tests

NA trial testing Tobacco smoking and nicotine patch in Smoking. Withdrawn.

Timeline
1 December 2019
Primary endpoint
30 October 2025
30 October 2025

Quick facts

Lead sponsorUniversity of Maryland, Baltimore
PhaseNA
StatusWithdrawn
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposebasic science
Start date1 December 2019
Primary completion30 October 2025
Estimated completion30 October 2025
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

University of Maryland, Baltimore

Who can join

Adults 18 to 60, any sex, with Smoking. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

People living with HIV-1 have high rates of cigarette smoking, which may be related to nicotinic interaction with HIV-1 infection and brain function levels. The proposed project aims to understand these pathways using translational brain imaging and HIV-1 reactivation studies. The study proposes a targeted nicotine-brain investigation of the nicotinic effects in HIV-1 infection from cellular to brain circuitry levels.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Smoking

Currently open trials in the same condition.

Other University of Maryland, Baltimore trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03308331.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing